Ani Pharmaceuticals Inc Sample Contracts

CONFIDENTIAL
Biosante Pharmaceuticals Inc • February 24th, 2000 • Biological products, (no disgnostic substances) • Illinois
AutoNDA by SimpleDocs
R E C I T A L S:
Shareholders' Agreement • December 23rd, 1999 • Ben Abraham Technologies Inc • Illinois
FORM C ESCROW AGREEMENT
Escrow Agreement • December 23rd, 1999 • Ben Abraham Technologies Inc • Ontario
FIRST AMENDMENT TO LEASE
Lease • March 26th, 2004 • Biosante Pharmaceuticals Inc • Biological products, (no disgnostic substances)
CONFIDENTIAL
Biosante Pharmaceuticals Inc • March 30th, 2001 • Biological products, (no disgnostic substances) • Illinois
RECITALS
Sublease Agreement • September 14th, 2001 • Biosante Pharmaceuticals Inc • Biological products, (no disgnostic substances)
BETWEEN
License Agreement • July 11th, 2000 • Biosante Pharmaceuticals Inc • Biological products, (no disgnostic substances) • Illinois
Common Stock Purchase Warrant BIOSANTE PHARMACEUTICALS, INC.
Biosante Pharmaceuticals Inc • December 29th, 2010 • Biological products, (no disgnostic substances)

THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to the close of business on the five year anniversary of the Initial Exercise Date (the “Termination Date”) but not thereafter, to subscribe for and purchase from BioSante Pharmaceuticals, Inc., a Delaware corporation (the “Company”), up to shares (the “Warrant Shares”) of Common Stock.

SECURITIES PURCHASE AGREEMENT
Securities Purchase Agreement • August 17th, 2012 • Biosante Pharmaceuticals Inc • Biological products, (no disgnostic substances) • New York

This Securities Purchase Agreement (this “Agreement”) is dated as of August 16, 2012, between BioSante Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).

RECITALS
Employment Agreement • March 30th, 2001 • Biosante Pharmaceuticals Inc • Biological products, (no disgnostic substances) • Illinois
OFFICE LEASE BETWEEN
Biosante Pharmaceuticals Inc • March 26th, 2004 • Biological products, (no disgnostic substances)

LASALLE BANK NATIONAL ASSOCIATION, AS SUCCESSOR TRUSTEE TO AMERICAN NATIONAL BANK AND TRUST COMPANY OF CHICAGO, as Trustee under Trust Agreement dated January 1, 1991 and known as Trust No. 113370-03

SECURITIES PURCHASE AGREEMENT
Securities Purchase Agreement • August 14th, 2009 • Biosante Pharmaceuticals Inc • Biological products, (no disgnostic substances) • New York

This Securities Purchase Agreement (this “Agreement”) is dated as of August 13, 2009, between BioSante Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).

WARRANT
Biosante Pharmaceuticals Inc • May 14th, 2004 • Biological products, (no disgnostic substances)
VOTING AGREEMENT ----------------
Voting Agreement • December 23rd, 1999 • Ben Abraham Technologies Inc • Illinois
RECITALS
Registration Rights Agreement • December 23rd, 1999 • Ben Abraham Technologies Inc • Illinois
CONFIDENTIAL Stephen M. Simes President & Chief Executive Officer BioSante Pharmaceuticals, Inc.
Biosante Pharmaceuticals Inc • August 17th, 2012 • Biological products, (no disgnostic substances) • New York
AutoNDA by SimpleDocs
WITNESSETH:
Subscription Agreement • May 12th, 2004 • Biosante Pharmaceuticals Inc • Biological products, (no disgnostic substances) • Delaware
ARTICLE 1 INTERPRETATION
Arrangement Agreement • December 23rd, 1999 • Ben Abraham Technologies Inc • Ontario
FORM OF COMMON STOCK PURCHASE WARRANT To Purchase «Shares» Shares of Common Stock of BIOSANTE PHARMACEUTICALS, INC.
Biosante Pharmaceuticals Inc • August 6th, 2003 • Biological products, (no disgnostic substances) • New York

THIS IS TO CERTIFY THAT «Name», or registered assigns (the “Holder”), is entitled, during the Exercise Period (as hereinafter defined), to purchase from BioSante Pharmaceuticals, Inc., a Delaware corporation (the “Company”), the Warrant Stock (as hereinafter defined and subject to adjustment as provided herein), in whole or in part, at a purchase price of $2.15 per share, all on and subject to the terms and conditions hereinafter set forth.

REGISTRATION RIGHTS AGREEMENT
Registration Rights Agreement • December 18th, 2008 • Biosante Pharmaceuticals Inc • Biological products, (no disgnostic substances) • New York

This REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of December 15, 2008, is by and between BIOSANTE PHARMACEUTICALS INC. (the “Company”) and KINGSBRIDGE CAPITAL LIMITED (the “Investor”).

Common Stock Purchase Warrant BIOSANTE PHARMACEUTICALS, INC.
Biosante Pharmaceuticals Inc • August 17th, 2012 • Biological products, (no disgnostic substances)

THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to the close of business on the five year anniversary of the Initial Exercise Date (the “Termination Date”) but not thereafter, to subscribe for and purchase from BioSante Pharmaceuticals, Inc., a Delaware corporation (the “Company”), up to shares (the “Warrant Shares”) of Common Stock.

SECURITIES PURCHASE AGREEMENT
Securities Purchase Agreement • June 21st, 2010 • Biosante Pharmaceuticals Inc • Biological products, (no disgnostic substances) • New York

This Securities Purchase Agreement (this “Agreement”) is dated as of June 20, 2010, between BioSante Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).

1,898,735 Shares of Common Stock ANI PHARMACEUTICALS, INC. UNDERWRITING AGREEMENT
Underwriting Agreement • May 12th, 2023 • Ani Pharmaceuticals Inc • Pharmaceutical preparations • New York

ANI Pharmaceuticals, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the several underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 1,898,735 shares (the “Firm Shares”) of its common stock, par value $0.0001 per share (the “Common Stock”). The Company also proposes to issue and sell to the several Underwriters up to an additional 284,810 shares (the “Additional Shares”) of Common Stock at the option of the Underwriters as provided in Section 2(c) below. The Firm Shares and any Additional Shares purchased by the Underwriters are referred to herein as the “Shares.” Guggenheim Securities, LLC (“Guggenheim Securities”) is acting as representative (the “Representative”) of the several Underwriters in connection with the offering and sale of the Shares contemplated herein (the “Offering”).

COMMON STOCK PURCHASE AGREEMENT by and between KINGSBRIDGE CAPITAL LIMITED and BIOSANTE PHARMACEUTICALS INC. dated as of December 15, 2008
Common Stock Purchase Agreement • December 18th, 2008 • Biosante Pharmaceuticals Inc • Biological products, (no disgnostic substances) • New York

This COMMON STOCK PURCHASE AGREEMENT (this “Agreement”) is entered into as of the 15th day of December, 2008, by and between Kingsbridge Capital Limited, an entity organized and existing under the laws of the British Virgin Islands, whose business address is P.O. Box 1075, Elizabeth House, 9 Castle Street, St. Helier, Jersey, Channel Islands (the “Investor”), and BioSante Pharmaceuticals Inc., a corporation organized and existing under the laws of the State of Delaware (the “Company”).

Common Stock Purchase Warrant BIOSANTE PHARMACEUTICALS, INC.
Biosante Pharmaceuticals Inc • March 4th, 2011 • Biological products, (no disgnostic substances)

THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to the close of business on the three year anniversary of the Initial Exercise Date (the “Termination Date”) but not thereafter, to subscribe for and purchase from BioSante Pharmaceuticals, Inc., a Delaware corporation (the “Company”), up to shares (the “Warrant Shares”) of Common Stock.

16,000,000 Shares BioSante Pharmaceuticals, Inc. Common Stock, $0.0001 Par Value per Share UNDERWRITING AGREEMENT
Underwriting Agreement • July 28th, 2011 • Biosante Pharmaceuticals Inc • Biological products, (no disgnostic substances) • New York

Introductory. BioSante Pharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) an aggregate of 16,000,000 shares of its common stock, par value $0.0001 per share (the “Common Stock”). The 16,000,000 shares of Common Stock to be sold by the Company are collectively called the “Firm Shares.” In addition, the Company has granted to the Underwriters an option to purchase up to an additional 2,400,000 shares of Common Stock as provided in Section 2. The additional 2,400,000 shares of Common Stock to be sold by the Company pursuant to such option are collectively called the “Optional Shares.” The Firm Shares and, if and to the extent such option is exercised, the Optional Shares are collectively called the “Offered Shares.” Jefferies & Company, Inc. (“Jefferies”) has agreed to act as representative of the several Underwriters (in such capacity, the “Representative”) in connection with the o

FORM OF NON-STATUTORY STOCK OPTION AGREEMENT (Non-Employee Director)
Form of Non-Statutory Stock Option Agreement • April 4th, 2014 • Ani Pharmaceuticals Inc • Pharmaceutical preparations • Delaware

THIS NON-STATUTORY STOCK OPTION AGREEMENT is entered into and effective as of this day of , (the "Date of Grant"), by and between ANI Pharmaceuticals, Inc. (the "Company") and (the "Optionee").

ANI PHARMACEUTICALS, INC. AND THE BANK OF NEW YORK MELLON, as Trustee FIRST SUPPLEMENTAL INDENTURE Dated as of December 10, 2014 3.00% Convertible Senior Notes due 2019
Supplemental Indenture • December 10th, 2014 • Ani Pharmaceuticals Inc • Pharmaceutical preparations

FIRST SUPPLEMENTAL INDENTURE (this “First Supplemental Indenture”) dated as of December 10, 2014 between ANI PHARMACEUTICALS, INC., a Delaware corporation, as issuer (the “Company”) and THE BANK OF NEW YORK MELLON, a New York banking corporation, as trustee (the “Trustee”).

Time is Money Join Law Insider Premium to draft better contracts faster.